RSCM
ACRS icon

Rock Springs Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Rock Springs Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.8M Buy
4,472,650
+18,909
+0.4% +$63.8K 0.99% 34
2025
Q4 		$13.4M Sell
4,453,741
-155,568
-3% -$393K 0.69% 45
2025
Q3 		$8.76M Sell
4,609,309
-160,000
-3% -$279K 0.51% 54
2025
Q2 		$6.77M Sell
4,769,309
-277,000
-5% -$375K 0.42% 57
2025
Q1 		$7.72M Sell
5,046,309
-1,158,000
-19% -$2.47M 0.44% 57
2024
Q4 		$15.4M Buy
6,204,309
+3,450,814
+125% +$8.59M 0.59% 52
2024
Q3 		$3.17M Hold
2,753,495
– – 0.1% 93
2024
Q2 		$3.03M Hold
2,753,495
– – 0.09% 94
2024
Q1 		$3.41M Sell
2,753,495
-245,000
-8% -$292K 0.09% 100
2023
Q4 		$3.15M Sell
2,998,495
-961,954
-24% -$2.93M 0.08% 88
2023
Q3 		$27.1M Sell
3,960,449
-1,400
-0% -$12K 0.73% 46
2023
Q2 		$41.1M Hold
3,961,849
– – 0.98% 35
2023
Q1 		$32.1M Buy
3,961,849
+600
+0% +$7.62K 0.76% 46
2022
Q4 		$62.4M Hold
3,961,249
– – 1.5% 23
2022
Q3 		$62.4M Buy
3,961,249
+34,100
+0.9% +$537K 1.61% 18
2022
Q2 		$54.8M Buy
3,927,149
+62,115
+2% +$870K 1.6% 20
2022
Q1 		$66.6M Buy
3,865,034
+3,687
+0.1% +$50.3K 1.68% 19
2021
Q4 		$56.1M Buy
3,861,347
+58,115
+2% +$880K 1.3% 25
2021
Q3 		$68.5M Buy
3,803,232
+40,920
+1% +$656K 1.44% 21
2021
Q2 		$66.1M Buy
3,762,312
+193,120
+5% +$4.39M 1.31% 22
2021
Q1 		$89.9M Buy
3,569,192
+893,092
+33% +$17.5M 1.96% 11
2020
Q4 		$17.3M Buy
2,676,100
+599,793
+29% +$2.53M 0.37% 83
2020
Q3 		$5.34M Buy
2,076,307
+432,292
+26% +$967K 0.14% 128
2020
Q2 		$2.66M Buy
1,644,015
+44,015
+3% +$59K 0.07% 134
2020
Q1 		$1.66M Hold
1,600,000
– – 0.07% 121
2019
Q4 		$3.02M Sell
1,600,000
-1,374,754
-46% -$2.28M 0.1% 113
2019
Q3 		$3.21M Buy
2,974,754
+946,754
+47% +$1.34M 0.13% 120
2019
Q2 		$4.44M Buy
2,028,000
+328,000
+19% +$1.79M 0.16% 109
2019
Q1 		$10.2M Buy
1,700,000
+370,600
+28% +$2.46M 0.39% 80
2018
Q4 		$9.82M Buy
1,329,400
+449,400
+51% +$4.63M 0.46% 70
2018
Q3 		$12.8M Buy
880,000
+24,000
+3% +$411K 0.46% 70
2018
Q2 		$17.1M Buy
856,000
+326,000
+62% +$6.02M 0.66% 50
2018
Q1 		$9.29M Buy
530,000
+115,000
+28% +$2.44M 0.4% 81
2017
Q4 		$10.2M Sell
415,000
-25,000
-6% -$609K 0.46% 74
2017
Q3 		$11.4M Hold
440,000
– – 0.52% 64
2017
Q2 		$11.9M Sell
440,000
-235,000
-35% -$6.39M 0.6% 53
2017
Q1 		$20.1M Sell
675,000
-425,000
-39% -$12.3M 1.16% 29
2016
Q4 		$29.9M Buy
1,100,000
+84,000
+8% +$2.14M 2% 13
2016
Q3 		$26M Buy
1,016,000
+16,000
+2% +$339K 1.63% 19
2016
Q2 		$18.5M Buy
1,000,000
+104,500
+12% +$2.07M 1.37% 22
2016
Q1 		$17M Sell
895,500
-654
-0.1% -$12.5K 1.42% 20
2015
Q4 		$24.1M Buy
+896,154
New +$17.5M 1.83% 15

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Rock Springs Capital Management's ACRS Position: Q1 2026 in Review

Rock Springs Capital Management increased its Aclaris Therapeutics (ACRS) stake by 0.42% in Q1 2026, buying an estimated $63.8K and bringing the position to 4,472,650 shares worth $16.8M. The position accounts for 0.99% of the portfolio, ranked #34.

Rock Springs Capital Management first reported a position in ACRS in Q4 2015 and has held it in 42 quarters since. The position peaked at $89.9M in Q1 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Rock Springs Capital Management held 4,472,650 shares of Aclaris Therapeutics worth $16.8M as of Q1 2026.
  • Rock Springs Capital Management bought 18,909 Aclaris Therapeutics shares in Q1 2026, an estimated $63.8K.
  • Aclaris Therapeutics made up 0.99% of Rock Springs Capital Management's portfolio in Q1 2026, its #34 holding.
  • Rock Springs Capital Management first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • Rock Springs Capital Management's Aclaris Therapeutics position peaked at $89.9M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.